Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at William Blair reduced their Q1 2018 EPS estimates for shares of Charles River Laboratories International in a research report issued on Wednesday. William Blair analyst J. Kreger now anticipates that the medical research company will post earnings per share of $1.32 for the quarter, down from their prior forecast of $1.37. William Blair also issued estimates for Charles River Laboratories International’s Q2 2018 earnings at $1.46 EPS, Q3 2018 earnings at $1.39 EPS, Q4 2018 earnings at $1.38 EPS, FY2018 earnings at $5.56 EPS and FY2020 earnings at $6.78 EPS.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The firm had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. During the same period in the prior year, the business earned $1.18 EPS. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/q1-2018-eps-estimates-for-charles-river-laboratories-international-inc-reduced-by-analyst-crl/1710627.html.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Monday. Robert W. Baird set a $117.00 price target on Charles River Laboratories International and gave the stock a “buy” rating in a research note on Monday. ValuEngine downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Bank of America Corporation cut their price target on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 price target (up from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Charles River Laboratories International currently has a consensus rating of “Buy” and a consensus target price of $106.05.

Charles River Laboratories International (NYSE CRL) traded down $0.08 on Friday, hitting $101.39. The stock had a trading volume of 376,906 shares, compared to its average volume of 382,004. Charles River Laboratories International has a 52 week low of $69.51 and a 52 week high of $119.05. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. The stock has a market cap of $4,810.00, a P/E ratio of 19.83, a PEG ratio of 1.61 and a beta of 0.94.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The disclosure for this sale can be found here. In the last three months, insiders have bought 10,500 shares of company stock worth $2,885 and have sold 1,012,147 shares worth $1,591,514. Corporate insiders own 2.20% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alps Advisors Inc. grew its holdings in Charles River Laboratories International by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after buying an additional 14 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Charles River Laboratories International by 0.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock valued at $703,000 after buying an additional 33 shares during the last quarter. Bbva Compass Bancshares Inc. grew its holdings in Charles River Laboratories International by 0.8% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock valued at $607,000 after buying an additional 50 shares during the last quarter. World Asset Management Inc grew its holdings in Charles River Laboratories International by 2.2% in the 2nd quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock valued at $279,000 after buying an additional 59 shares during the last quarter. Finally, M&T Bank Corp grew its holdings in Charles River Laboratories International by 1.8% in the 2nd quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock valued at $441,000 after buying an additional 76 shares during the last quarter. 97.46% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.